DNR METILINIMO POKYČIAI PERIFERINIO KRAUJO LEUKOCITUOSE PACIENTAMS, SERGANTIEMS SKRANDŽIO VĖŽIU

Gastric cancers are usually diagnosed at an advanced stage in the progression of the disease, thus reducing the survival chances of the patients. Non-invasive early detection would greatly enhance therapy and survival rates. For this aim, we investigated tumor suppressor genes CDKN2A/p16, RARBeta, TNFRSF10C, APC, ACIN1, DAPK1, 3OST2, BCL2 and CD44 for methylation changes in peripheral blood leukocytes of gastric cancer patients. This study shows that methylation changes in peripheral blood leukocyte DNA could provide a promising method for the early detection of gastric cancer. However, larger studies are essential to explore the clinical usefulness of a peripheral blood leukocyte DNA methylation based tests for non-invasive early detection of gastric cancer.

Download Full-text

Short telomere length in peripheral blood leukocyte predicts poor prognosis and indicates an immunosuppressive phenotype in gastric cancer patients

Molecular Oncology ◽

10.1016/j.molonc.2014.11.008 ◽

2014 ◽

Vol 9 (3) ◽

pp. 727-739 ◽

Cited By ~ 15

Author(s):

Falin Qu ◽

Renli Li ◽

Xianli He ◽

Qiucheng Li ◽

Shuang Xie ◽

...

Keyword(s):

Gastric Cancer ◽

Telomere Length ◽

Cancer Patients ◽

Peripheral Blood ◽

Poor Prognosis ◽

Peripheral Blood Leukocyte ◽

Short Telomere ◽

Blood Leukocyte ◽

Gastric Cancer Patients

Download Full-text

Association of ZNF331 and WIF1 methylation in peripheral blood leukocytes with the risk and prognosis of gastric cancer

BMC Cancer ◽

10.1186/s12885-021-08199-4 ◽

2021 ◽

Vol 21 (1) ◽

Author(s):

Chuang Nie ◽

Xu Han ◽

Rongrong Wei ◽

Anastasiia Leonteva ◽

Jia Hong ◽

...

Keyword(s):

Gastric Cancer ◽

Dna Methylation ◽

Peripheral Blood ◽

Cox Regression ◽

Methylation Status ◽

Surrogate Marker ◽

Peripheral Blood Leukocyte ◽

Blood Leukocytes ◽

Potential Biomarker ◽

Blood Leukocyte

Abstract Background Peripheral blood leukocyte (PBL) DNA methylation may serve as a surrogate marker to evaluate the susceptibility to and prognosis of gastric cancer (GC). In this study, blood-derived DNA methylation levels of two tumour-related genes, namely, ZNF331 and WIF1, and their impacts on the risk and prognosis of GC were evaluated. Methods In total, 398 GC cases and 397 controls were recruited for the study. Then, all cases were followed up for 5 years. ZNF331 and WIF1 promoter methylation status in PBLs was measured using a methylation-sensitive high-resolution melting method. Logistic and Cox regression models were used to analyse the correlation between gene methylation and the risk and prognosis of GC. Confounders were balanced through propensity score (PS) matching. Results High ZNF331 methylation significantly decreased GC risk after PS adjustment (OR = 0.580, 95% CI: 0.375–0.898, P = 0.015), which also presented in males (OR = 0.577, 95% CI: 0.343–0.970, P = 0.038). However, WIF1 methylation was not associated with GC risk. Additionally, significant combined effects between ZNF331 methylation and the intake of green vegetables and garlic were observed (OR = 0.073, 95% CI: 0.027–0.196, P < 0.001 and OR = 0.138, 95% CI: 0.080–0.238, P < 0.001, respectively). Furthermore, ZNF331 and WIF1 methylation had no impact on the prognosis of GC. Conclusion ZNF331 methylation in PBLs may affect GC risk in combination with the consumption of green vegetables and garlic and may act as a potential biomarker of GC.

Download Full-text

Detection of viable human circulating tumor cells using telomerase-specific GFP-expressing bioengineered adenovirus in patients with gastric cancer: A feasibility study.

Journal of Clinical Oncology ◽

10.1200/jco.2011.29.4_suppl.18 ◽

2011 ◽

Vol 29 (4_suppl) ◽

pp. 18-18

Author(s):

T. Fujiwara ◽

F. Uno ◽

Y. Hashimoto ◽

Y. Shirakawa ◽

T. Nagasaka ◽

...

Keyword(s):

Gastric Cancer ◽

Viral Replication ◽

Tumor Cells ◽

Circulating Tumor Cells ◽

Peripheral Blood ◽

Fluorescent Protein ◽

Human Tumor ◽

Blood Leukocytes ◽

Systemic Treatments ◽

Gastric Cancer Patients

18 Background: The presence of circulating tumor cells (CTC) in the peripheral blood is associated with short survival and, therefore, the detection of CTC is clinically useful as prognostic factors of disease outcome and/or surrogate markers of treatment response. Recent technical advances in immunocytometric analysis and quantitative real-time PCR have made possible to detect a few CTC in the blood; however, there is no sensitive assay for detecting viable CTC. We developed a new approach to visually detect live CTC among millions of peripheral blood leukocytes using telomerase-specific replication-selective adenovirus expressing green fluorescent protein (GFP). Methods: We constructed a GFP-expressing attenuated adenovirus, in which the telomerase promoter regulates viral replication (OBP-401, TelomeScan). The detection method for viable human CTC in the peripheral blood involves a three-step procedure including the lysis of red blood cells, the subsequent addition of OBP-401 to the cell pellets, and the automated scan under the fluorescent microscope. We analyzed fresh blood samples collected from 37 patients with histologically confirmed gastric cancer. We further assessed the CTC dynamics in patients who were undergoing chemotherapy or surgery to demonstrate the clinical potential of our approach for monitoring treatment responses. Results: OBP-401 increased the signal-to-background ratio as a tumor-specific probe, because the fluorescent signal can be amplified only in viable human tumor cells by viral replication. Although the CTC level varied widely, ranging from 0 to 47 in 5-ml samples, 26 gastric cancer patients (70.3%) had more than one CTC; there was, however, no apparent relationship between CTC counts and TNM stages. Patients who had a recurrence of gastric cancer had decreased CTC counts after systemic chemotherapy. In the patients who underwent surgery, the CTC level dropped after complete resection. Conclusions: This GFP-expressing virus-based method is simple and allows precise enumeration of CTC, which might be useful for monitoring the efficacy of local and systemic treatments. [Table: see text]

Download Full-text

Lymphopenia and DMTs for relapsing forms of MS

Neurology Clinical Practice ◽

10.1212/cpj.0000000000000567 ◽

2019 ◽

Vol 9 (1) ◽

pp. 53-63 ◽

Cited By ~ 8

Author(s):

Edward J. Fox ◽

Guy J. Buckle ◽

Barry Singer ◽

Vibhuti Singh ◽

Aaron Boster

Keyword(s):

Peripheral Blood ◽

Immune Surveillance ◽

Drug Efficacy ◽

Peripheral Blood Leukocyte ◽

Patient Characteristics ◽

Blood Leukocytes ◽

Leukocyte Counts ◽

Absolute Lymphocyte Counts ◽

Blood Leukocyte

Purpose of reviewTo provide neurologists with an update on the proposed mechanisms of action (MOAs) of disease-modifying therapies (DMTs) for the treatment of relapsing MS, and their effect on peripheral blood leukocytes, in order to inform treatment decisions.Recent findingsDMTs have vastly differing MOAs, including effects on peripheral blood leukocyte counts, particularly lymphocytes. The clinical implications of changes in lymphocyte counts need to be understood in the context of the underlying MOAs of each respective DMT, with treatment tailored to individual patient needs.SummaryDMTs can alter lymphocyte counts, subsets, activation, and distribution, and thus can influence immune surveillance. Serial monitoring of total leukocytes and absolute lymphocyte counts (ALCs) is advisable in patients receiving DMTs. ALCs should be interpreted regarding expected immunologic changes and individual patient characteristics. Any decision to switch DMTs should consider these factors, along with drug efficacy, safety, and effect on quality of life.

Download Full-text